Ziconotide

Mechanism

An extremely potent pain-killing peptide derived from cone snail venom. It's about 1000x more powerful than morphine and doesn't cause addiction. The catch: it must be delivered directly into the spinal fluid via an implanted pump because it can't cross the blood-brain barrier. FDA-approved for severe chronic pain when nothing else works.

Effects

## Nervous System — Pain Signaling [Tier 1 — FDA-Approved Indication] Ziconotide is a synthetic form of omega-conotoxin MVIIA, derived from the cone snail Conus magus. It selectively and reversibly blocks N-type voltage-gated calcium channels (Cav2.2) in the dorsal horn of the spinal cord. By blocking presynaptic calcium influx at primary afferent nerve terminals, it prevents release of pro-nociceptive neurotransmitters (substance P, glutamate, CGRP) in the spinal dorsal horn. This produces potent analgesia without binding opioid receptors — no tolerance, no respiratory depression, no addiction potential. The analgesic effect is confined to spinal cord pathways because it is delivered intrathecally and does not cross the blood-brain barrier. ## Central Nervous System — Psychiatric/Cognitive Effects [Tier 1 — Post-Marketing Data] CNS side effects are the major dose-limiting toxicity. Ziconotide causes dose-dependent cognitive impairment (confusion, memory impairment), psychiatric effects (hallucinations, psychosis, paranoia, depression, suicidal ideation), and somnolence. These effects are thought to result from calcium channel blockade in supraspinal neurons exposed to drug via CSF circulation. Incidence of severe psychiatric events: ~2-5% at recommended doses. These are generally reversible upon dose reduction or discontinuation, though resolution may take weeks due to slow CSF clearance. ## Cardiovascular System [Tier 1 — Clinical Data] Ziconotide can cause postural hypotension via blockade of sympathetic preganglionic N-type calcium channels in the spinal cord. Clinically significant hypotension occurs in approximately 5-9% of patients. ## Neuromuscular System [Tier 2 — Clinical Data] Nystagmus, dizziness, ataxia, and abnormal gait are common (20-45% incidence). These vestibular/cerebellar effects limit dose titration and are the most frequently reported adverse events. Elevated creatine kinase (CK) occurs in ~40% of patients, usually asymptomatic, but rhabdomyolysis has been reported rarely.

Practitioner Guide

## Intrathecal Delivery — The Only Route Ziconotide has zero oral bioavailability and does not cross the blood-brain barrier. It MUST be delivered intrathecally via an implanted programmable pump (SynchroMed II or equivalent) or external microinfusion device. This limits use to specialized pain management centers. ### Patient Selection - **Indicated for:** Severe chronic pain in patients refractory to or intolerant of other analgesic therapies (opioids, nerve blocks, spinal cord stimulation). Most commonly used in cancer pain and chronic non-cancer pain (CRPS, failed back surgery syndrome, neuropathic pain). - **Pre-treatment requirements:** Baseline CK level, psychiatric evaluation (screen for depression, psychosis, suicidal ideation), cognitive assessment. - **Contraindicated in:** Pre-existing psychosis, suicidal ideation, history of psychosis, infection at the microinfusion site, uncontrolled bleeding diathesis, spinal canal obstruction. ### Dosing Protocol - **Starting dose:** 0.5 mcg/day (2.4 mcg/day was the original starting dose but caused unacceptable side effects — the "low and slow" approach is now standard). - **Titration:** Increase by no more than 0.5 mcg/day, no more frequently than 2-3 times per week. Many practitioners titrate weekly. - **Effective dose range:** 2.4-19.2 mcg/day. Most patients stabilize at 3-8 mcg/day. - **Maximum dose:** 19.2 mcg/day (higher doses have been used off-label but with significantly more side effects). - **Time to effect:** Analgesia may begin within hours, but optimal titration takes 2-3 weeks. ### Managing Side Effects - **Cognitive/psychiatric effects:** Titrate slowly. If psychosis or severe confusion develops, reduce dose by 50% or discontinue. Monitor for suicidal ideation at every visit. Consider baseline and periodic MMSE or MoCA testing. - **Nystagmus/dizziness:** Most common reason for dose limitation. Often improves with slow titration. May not fully resolve at therapeutic doses — discuss trade-off with patient. - **Elevated CK:** Monitor CK at baseline, monthly for first 2 months, then quarterly. If CK >3x ULN with symptoms (myalgia, weakness), consider dose reduction. Discontinue if rhabdomyolysis suspected. - **Pump-related considerations:** Use preservative-free formulation only. Refill intervals typically 1-3 months. Pump pocket infections, catheter kinking, and granuloma formation at catheter tip are procedural risks. ### Clinical Pearls - Ziconotide can be combined with intrathecal opioids (morphine, hydromorphone) in the same pump. The Polyanalgesic Consensus Conference (PACC) guidelines recommend ziconotide as a first-line intrathecal agent alongside morphine. - Unlike intrathecal opioids, ziconotide does not cause tolerance. Patients often maintain stable doses for years. - Abrupt discontinuation does not cause withdrawal (unlike intrathecal opioids), but pain will return. - Transition from intrathecal opioids to ziconotide should be done gradually to avoid opioid withdrawal.

Dosing Protocols

Contraindications & Cautions

• hard stop — Pregnancy
  No adequate human data. Intrathecal drug delivery during pregnancy poses additional procedural risks.
  Action: Do not use during pregnancy unless benefits clearly outweigh risks. Specialist decision only.
• hard stop — Intravenous administration
  Ziconotide (Prialt) is approved for INTRATHECAL use ONLY. Intravenous administration is dangerous and could cause severe systemic toxicity. The drug must be delivered directly into the cerebrospinal fluid via intrathecal pump.
  Action: INTRATHECAL ONLY. Never administer intravenously, subcutaneously, intramuscularly, or by any route other than intrathecal.
• hard stop — Breastfeeding
  No data on excretion in breast milk. CNS-active drug exposure in nursing infant is unacceptable risk.
  Action: Do not use while breastfeeding.
• hard stop — Active CNS infection
  Intrathecal delivery requires intact CNS barriers. Active CNS infection is a contraindication for intrathecal drug administration.
  Action: Do not use during active CNS infection. Treat infection first.
• hard stop — Under 18 years of age
  Intrathecal analgesic. Not for pediatric use outside specialist care.
  Action: Do not provide to individuals under 18.
• requires physician — Psychiatric disorders
  Ziconotide can cause severe psychiatric symptoms including psychosis, hallucinations, paranoid reactions, hostility, delirium, and changes in mental status. These effects may be dose-related and can occur at any time during therapy.
  Action: Requires psychiatric evaluation before initiation. Careful dose titration essential. Monitor mental status closely. Discontinue if psychiatric symptoms emerge.
• requires physician — History of suicidal ideation
  Ziconotide prescribing information warns about increased risk of suicide in patients with history of psychiatric illness or suicidal ideation. Depression and cognitive impairment are common side effects.
  Action: Requires careful psychiatric risk assessment. Close monitoring for mood changes. Ensure mental health support is in place.

Evidence

• A randomized, double-blind, placebo-controlled study of intrathecal ziconotide in adults with severe chronic pain

  Rauck RL, Wallace MS, Leong MS, Minehart M, Webster LR, Charapata SG, Abraham JE, Buffington DE, Ellis D, Kartzinel R (2006) — Journal of Pain and Symptom Management — PMID: 16488350

  Slow-titration intrathecal ziconotide significantly reduced chronic pain scores vs placebo with improved tolerability compared to the rapid-titration Staats trial. Slower dose escalation reduced the incidence of CNS adverse events (dizziness, confusion, nystagmus). Confirmed non-opioid analgesic efficacy for refractory neuropathic and nociceptive pain. Demonstrates that titration strategy is critical for ziconotide tolerability.

  strong

• Intrathecal ziconotide in the treatment of refractory pain in patients with cancer or AIDS: a randomized controlled trial

  Staats PS, Yearwood T, Charapata SG, Presley RW, Wallace MS, Byas-Smith M, Fisher R, Bryce DA, Mangieri EA, Luther RR, Mayo M, McGuire D, Ellis D (2004) — JAMA — PMID: 14722147

  Intrathecal ziconotide (synthetic omega-conotoxin MVIIA from cone snail venom) significantly reduced pain scores by 53% vs 18% with placebo in patients with refractory cancer or AIDS pain. The N-type calcium channel blocker provides analgesia through a non-opioid mechanism. FDA-approved as Prialt in 2004 for severe chronic pain refractory to other intrathecal therapies. Requires intrathecal pump delivery; narrow therapeutic window.

  strong

Research Summary

## Tier 1 — Strong Clinical Evidence (FDA-Approved) - FDA-approved (2004) for severe chronic pain via intrathecal delivery (Prialt, Jazz Pharmaceuticals) - Phase III trials demonstrated significant pain reduction: mean VASPI score improvement of 31.2% vs. 6.0% placebo in cancer/AIDS pain (Staats et al., JAMA 2004), and 14.7% vs. 7.2% in chronic non-cancer pain (Rauck et al., 2006) - Confirmed lack of tolerance development over long-term use (up to 7+ years in open-label extensions) - No addiction potential, no respiratory depression — critical advantages over intrathecal opioids ## Tier 2 — Moderate Evidence - Combination intrathecal therapy (ziconotide + opioid) may provide additive analgesia with lower doses of each agent (multiple case series, no RCT) - Low starting dose protocol (0.5 mcg/day) significantly reduces psychiatric adverse events compared to original FDA-approved starting dose (Deer et al., Neuromodulation 2012) - Post-marketing data suggest ~50-60% of patients achieve clinically meaningful pain reduction (≥30% VASPI improvement) ## Tier 3 — Preclinical/Theoretical - N-type calcium channel blockade may have applications beyond pain: preclinical data in neuroprotection (stroke, TBI), cardiac arrhythmia - Related conotoxins from other Conus species target different ion channel subtypes — ongoing drug discovery pipeline - Inhaled or transdermal delivery systems under investigation to overcome the intrathecal limitation (very early stage)